Şahap DEDE, Musa ŞAHPOLAT, MEHMET HANİFİ KOKAÇYA, Mustafa ARI, Cem SESLİOKUYUCU, Zafer YÖNDEN

Serum Apelin And Nesfatin-1 Levels in Depression Patients and Their Relationship with Treatment

Depresyon hastalarında serum apelin ve nesfatin-1 düzeyleri ve tedavi ile ilişkisi Amaç: Bu çalışma apelin ve nesfatin-1 moleküllerinin tedavi öncesi ve sonrası depresyonla ilişkisini ve biyolojik belirteç olarak kullanılıp kullanılamayacaklarını araştırmak amacıyla planlanmıştır. Yöntem: Çalışmaya psikiyatri polikliniğine başvuran 47 tedavisiz depresyon hastası ve 47 normal sağlıklı gönüllü alınmıştır. Tüm katılımcılara DSM-IV Eksen 1 Bozuklukları İçin Yapılandırılmış Klinik Görüşme (SCID-I), Hamilton Depresyon Ölçeği (HAM-D), Klinik Global İzlem (KGİ) Ölçeği uygulandı. Tedavi öncesinde ve tedavi başlangıcından sonraki 3. ayın sonunda 12 saat açlığı takiben periferik kan örnekleri alındı. Serum apelin ve nesfatin-1 düzeyleri ölçüldü. Bulgular: Kırkyedi depresyon hastasının 35'i (%74.5) kadın, 12'si (%25.5) erkekti. Kırkyedi gönüllünün 31'i (%66) kadın, 16'sı (%34) erkekti. Yaş, medeni durum, meslek ve Vücut Kitle İndeksi (VKİ) bakımından gruplar arasında fark yoktu. Başvuru serum apelin düzeyi hasta grubunda kontrol grubuna göre anlamlı derecede yüksekti. Hasta grubu ile kontrol grubu arasında başvuru serum nesfatin-1 düzeyi açısından anlamlı fark yoktu. Üç aylık tedavi sonrası hem serum apelin hem de serum nesfatin-1 düzeylerinde anlamlı fark oluşmamıştır. Sonuç: Çalışma bulgularımıza göre, serum apelin düzeyleri başvuru anında sağlıklı kontrollere göre anlamlı olarak yüksekti ve 3 aylık depresyon tedavisi (antidepresan, antidepresan + elektrokonvulsif terapi, antidepresan + terapi) sonrasında klinik iyileşmeye rağmen apelin düzeylerinde değişiklik saptanmadı. Hasta grubunda serum nesfatin-1 düzeyleri başvuru sırasında ve 3 aylık tedavi sonunda da kontrol grubundan farklı değildi. Çalışmamızda serum apelin düzeyi ile VKİ arasında ilişki saptanmamıştır. Başvuru sırasındaki serum nesfatin-1 düzeyi ile yine başvuru sırasında ölçülen VKİ arasında korelasyon tespit edilmiştir.

Depresyon hastalarında serum apelin ve nesfatin-1 düzeyleri ve tedavi ile ilişkisi

Serum apelin and nesfatin-1 levels in depression patients and their relationship with treatment Objective: This study was designed to investigate the molecules apelin and nesfatin-1, their relationship with depression before and after treatment, and whether they can be used as biomarkers. Method: Forty-seven depression patients referred to psychiatric outpatient clinic who were not on treatment and 47 normal healthy volunteers were enrolled in the study. The Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), the Hamilton Depression Rating Scale (HAM-D), and the Clinical Global Impression (CGI) Scale were administered to all participants. Peripheral blood samples were collected following a 12-hour fasting at the beginning and three months after the start of treatment. Serum apelin and nesfatin-1 levels were measured. Results: Of the 47 depression patients, 35 (74.5%) were females and 12 (25.5%) were males. Thirty-one (66%) of the 47 volunteers were females and 16 (34%) of them were males. Age, marital status, occupation and Body Mass Index (BMI) did not differ between the groups. Serum apelin level was significantly higher in the patient group than in the control group. There was no significant difference between the patient group and the control group in terms of serum nesfatin-1 levels. There was no significant difference in serum apelin and serum nesfatin-1 levels after 3 months of treatment. Conclusions: Serum apelin levels were significantly higher than healthy controls at the time of admission and there was no change in apelin levels after 3-months of treatment (antidepressant, antidepressant + electroconvulsive therapy, antidepressant + therapy) despite clinical recovery. Serum nesfatin-1 levels in the patient group were not different from the control group at the time of referral and at the end of 3 months treatment. There was no relationship between serum apelin level and BMI in our study. Serum nesfatin-1 level and BMI were correlated at the time of admission.

PDF

___

1. Angst J. Epidemiology of depression. Psycoparmacology (Berl) 1992; 106(Suppl):71-74. [CrossRef]
2. Koroglu E. Basic Psychiatry. Second ed. Ankara: Hekimler Yayin Birligi 2007: 240-64.
3. Akiskal HS. Mood Disorders: Introduction and overview. Compreh. Textbook of Psychiatry, 1st ed. Kaplan HI, Sadock BJ. PA: Williams and Wilkins 1995; 1067-1079.
4. Frasure-Smith N, Lesperance F, Talajic M. The impact of negative emotions on prognosis following myocardial infarction: is it more than depression? Health Psychol 1995; 14:388-398. [CrossRef]
5. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS; National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289:3095-3105. [CrossRef]
6. McIntyre RS, Konarski JZ, Wilkins K, Soczynska JK, Kennedy SH. Obesity in bipolar disorder and majör depressive disorder: results from a national community health survey on mental healt hand well-being. Can J Psychiatry 2006; 51:274-280.
7. McIntyre RS, Park KY, Law CW, Sultan F, Adams A, Lourenco MT, Lo AK, Soczynska JK, Woldeyohannes H, Alsuwaidan M, Yoon J, Kennedy SH. The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications. CNS Drugs 2010; 24:741-753. [CrossRef]
8. Weber-Hamann B, Kopf D, Lederbogen F, Gilles M, Heuser I, Colla M, Deuschle M. Activity of the hypothalamus-pituitaryadrenal system and oral glucose tolerance in depressed patients. Neuroendocrinology 2005; 81:200-204. [CrossRef]
9. Weber-Hamann B, Kratzsch J, Kopf D, Lederbogen F, Gilles M, Heuser I, Deuschle M. Resistin and adiponectin in major depression: the association with free cortisol and effects of antidepressant treatment. J Psychiatr Res 2007; 41:344-350. [CrossRef]
10. Oh-I S, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, Eguchi H, Yamamoto M, Imaki T, Hashimoto K, Tsuchiya T, Monden T, Horiguchi K, Yamada M, Mori M. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006; 443:709-712. [CrossRef]
11. Shimizu H, Oh-I S, Hashimoto K, Nakata M, Yamamoto S, Yoshida N, Eguchi H, Kato I, Inoue K, Satoh T, Okada S, Yamada M, Yada T, Mori M. Peripheral administration of nesfatin-1 reduces food intake in mice: the leptin-independent mechanism. Endocrinology 2009; 150:662-671. [CrossRef]
12. Ari M, Ozturk OH, Bez Y, Oktar S, Erduran D. High plasma nesfatin-1 level in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35:497-500. [CrossRef]
13. Merali Z, Cayer C, Kent P, Anisman H. Nesfatin-1 increases anxiety- and fear-related behaviors in the rat. Psychopharmacology (Berl) 2008; 201:115-123. [CrossRef]
14. Lv SY, Qin YJ, Wang HT, Xu N, Yang YJ, Chen Q. Centrally administered apelin-13 induces depression-like behavior in mice. Brain Res Bull 2012; 88:574-580. [CrossRef]
15. Ziora K, Oswiecimska J, Swietochowska, Ziora D, Ostrowska Z, Stojewska M, Klimacka-Nawrot E, Dyduch A, Błon’skaFajfrowska B. Assessment of serum apelin levels in girls with anorexia nervosa. J Clin Endocrinol Metab 2010; 95:2935-2941. [CrossRef]
16. Newson MJ, Pope GR, Roberts EM, Lolait SJ, O’Carroll AM. Stress-dependent and gender- specific neuroregulatory roles of the apelin receptor in the hypothalamic- pituitary-adrenal axis response to acute stress. J Endocrinol 2013; 216;99-109. [CrossRef]
17. Phillips ML, Vieta E. Identifying functional neuroimaging biomarkers of bipolar disorder: toward DSM-V. Schizophr Bull 2007; 33:893-904. [CrossRef]
18. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62. [CrossRef]
19. Akdemir A, Turkcapar MH, Orsel SD, Demirergi N, Dag I, Ozbay MH. Reliability and validity of the Turkish version of the Hamilton Depression Rating Scale. Compr Psychiatry 2001; 42:161-165. [CrossRef]
20. Guy W. Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health Education and Welfare, 1976; 218-222.
21. Taheri S, Murphy K, Cohen M, Sujkovic E, Kennedy A, Dhillo W, Dakin C, Sajedi A, Ghatei M, Bloom S. The effects of centrally administered apelin-13 on food intake, water intake and pituitary hormone release in rats. Biochem Biophys Res Commun 2002; 291:1208-1212. [CrossRef]
22. Lv SY, Yang YJ, Qin YJ, Mo JR, Wang NB, Wang YJ, Chen Q. Central apelin-13 inhibits food intake via the CRF receptor in mice. Peptides 2012; 33:132-138. [CrossRef]
23. Zhang CR, Xia CM, Jiang MY, Zhu MX, Zhu JM, Du DS, Liu M, Wang J, Zhu DN. Repeated electroacupuncture attenuating of apelin expression and function in the rostral ventrolateral medulla in stress-induced hypertensive rats. Brain Res Bull 2013; 97:53-62. [CrossRef]
24. Cheng B, Chen J, Bai B, Xin Q. Neuroprotection of apelin and its signaling pathway. Peptides 2012; 37:171-173. [CrossRef]
25. Krist J, Wieder K, Kloting N, Oberbach A, Kralisch S, Wiesner T, Schon MR, Gartner D, Dietrich A, Shang E, Lohmann T, Dreßler M, Fasshauer M, Stumvoll M, Bluher M. Effects of weight loss and exercise on apelin serum concentrations and adipose tissue expression in human obesity. Obes Facts 2013; 6:57-69. [CrossRef]
26. Soriguer F, Garrido-Sanchez L, Garcia-Serrano S, Garcia-Almeida JM, Garcia-Arnes J, Tinahones FJ, Garcia-Fuentes E. Apelin levels are increased in morbidly obese subjects with type 2 diabetes mellitus. Obes Surg 2009; 19:1574-1580. [CrossRef]
27. Castan-Laurell I, Vitkova M, Daviaud D, Dray C, Kovacikova M, Kovacova Z, Hejnova J, Stich V, Valet P. Effect of hypocaloric diet-induced weight loss in obese women on plasma apelin and adipose tissue expression of apelin and APJ. Eur J Endocrinol 2008; 158:905-910. [CrossRef]
28. Hofmann T, Stengel A, Ahnis A, Buße P, Elbelt U, Klapp BF.NUCB2/nesfatin-1 is associated with elevated scores of anxiety in female obese patients. Psychoendocrinology 2013; 38:2502-2510. [CrossRef]
29. Gunay H, Tutuncu R, Aydın S, Dag E, Abasli D. Decreased plasma nesfatin-1 levels in patients with generalized anxiety disorder. Psychoneuroendocrinology 2012; 37:1949-1953. [CrossRef]
30. Ahima RS, Flier JS. Leptin. Annu Rev Physiol 2000; 62:413-437. [CrossRef]
31. Emul M, Karamustafalioglu N, Kalelioglu T, Genc A, Tasdemir A, Gungor FC, Incir S, Seven A. The nesfatin-1 level in male patients with manic episode and alterations of nesfatin-1 level after antipsychotic and electroconvulsive treatment. J Affect Disord 2013; 151:849-853. [CrossRef]
32. Ogiso K, Asakawa A, Amitani H, Nakahara T, Ushikai M, Haruta I, Koyama K, Amitani M, Harada T, Yasuhara D, Inui A. Plasma nesfatin-1 concentrations in restricting-type anorexia nervosa. Peptides 2011; 32:150-153. [CrossRef]
33. Stengel A, Tache Y. Minireview: nesfatin-1, an emerging new player in the brain-gut, endocrine, and metabolic axis. Endocrinology 2011; 152:4033-4038. [CrossRef]
34. Tan BK, Hallschmid M, Kern W, Lehnert H, Randeva HS. Decreased cerebrospinal fluid/plasma ratio of the novel satiety molecule, nesfatin-1/NUCB-2, in obese humans: evidence of nesfatin-1/NUCB-2 resistance and implications for obesity treatment. J Clin Endocrinol Metab 2011; 96:E669-673. [CrossRef]
35. Stengel A, Hofmann T, Goebel-Stengel M, Lembke V, Ahnis A, Elbelt U, Lambrecht NW, Ordemann J, Klapp BF, Kobelt P. Ghrelinand NUCB2/nesfatin-1 are expressed in the same gastric cell and differentially correlated with body mass index in obese subjects. Histochem Cell Biol 2013; 139:909-918. [CrossRef]
36. Zegers D, Beckers S, Mertens IL, Van Gaal LF, Van Hul W. Association between polymorphisms of the Nesfatin gene, NUCB2, and obesity in men. Mol Genet Metab 2011; 103:282- 286. [CrossRef]